Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT06464653

Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut Syndrome

Sponsor: Liankun_Ren

View on ClinicalTrials.gov

Summary

The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of pallidothalamic tracts as adjunctive therapy for alleviating symptoms in Lennox-Gastaut Syndrome.

Official title: The Efficacy and Safety of Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut Syndrome: A Prospective, Pilot Trial

Key Details

Gender

All

Age Range

14 Years - 35 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-05-01

Completion Date

2025-12-30

Last Updated

2025-07-30

Healthy Volunteers

Conditions

Lennox Gastaut Syndrome

Interventions

DEVICE

Forel's Field H-DBS ON

The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy. The targets used in this study is Forel's Field H. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.

Inclusion Criteria: 1. Meets the diagnostic criteria for Lennox-Gastaut Syndrome (LGS) based on comprehensive assessment of medical history, seizure semiology, and electroencephalographic (EEG) findings during both ictal and interictal periods; 2. Interictal EEG demonstrates generalized paroxysmal fast activity (GPFA) and slow spike-and-wave (SSW) complexes; 3. Generalized tonic-clonic seizures (GTCs) have been captured in prior video-EEG monitoring, or seizure episodes have been clearly described by reliable eyewitnesses; 4. During the screening or baseline period, the following conditions are met: 1. The patient or caregiver is capable of reliably maintaining a seizure diary; 2. The seizure diary indicates an average of at least 5 seizures per month; 3. The patient is on two or more antiepileptic drugs (AEDs), with a stable treatment regimen (no new add-on or withdrawal of AEDs, excluding temporary rescue medications such as benzodiazepines; dose adjustments are allowed); 5. The patient has been evaluated through a comprehensive presurgical epilepsy workup and is considered unsuitable for, or has declined, resective epilepsy surgery, or has had unsatisfactory outcomes from resective or ablative procedures; 6. Providation of written informed consent, demonstrates adequate compliance with the study protocol, and agrees to participate in this clinical study. Exclusion Criteria: 1. Unable to provide a reliable seizure diary by self or legal guardian; 2. Predominant seizure type is focal impaired awareness seizures; 3. Psychogenic non-epileptic seizures within 12 months; 4. Brain structual abnormalities precluding safe implantation of deep brain stimulator; 5. Conditions associated with increased risk of intraoperative or postoperative bleeding (e.g., coagulopathy), or requirement for long-term oral anticoagulant or antiplatelet therapy; 6. Presence of other severe somatic or internal medical conditions, including significant hepatic or renal dysfunction; 7. Pregnant, or planning to pregnant within 2 years.

Locations (1)

Xuanwu Hospital,Capital Medical University

Beijing, Beijing Municipality, China